{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T14:28:52Z","timestamp":1758205732578,"version":"3.44.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"17-18","license":[{"start":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T00:00:00Z","timestamp":1740873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T00:00:00Z","timestamp":1740873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>In recent years there has been an increase in the diagnoses of sexually transmitted infections (STI) among men who have sex with men (MSM) using human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP); however, data on PrEP users in Austria are limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients, material and methods<\/jats:title>\n            <jats:p>In June 2020, we initiated a\u00a0prospective observational cohort study at Vienna General Hospital including PrEP users from Vienna. Participants underwent STI testing quarterly and provided behavioral information using a\u00a0questionnaire.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Between June 2020 and December 2023 a total of 360 individuals (99% MSM) were enrolled comprising 379 person-years of follow-up. We identified 276 STIs in 154 individuals, of which 23% (36\/154) were symptomatic. The incidence rates per 100 person-years were 29.9 (95% confidence interval, CI 24.3\u201335.3 per 100 person-years) for gonorrhea, 22.7 (95% CI 17.9\u201327.5 per 100 person-years) for chlamydia and 9.8 (95% CI 6.6\u201312.9 per 100 person-years) for syphilis. Extragenital infections accounted for 95% (97\/102) of gonorrhea and 81% (65\/80) of chlamydia cases. A case of HIV infection was recorded in a\u00a020-year-old male with inconsistent PrEP use. Participants with one or more reinfection (18%; 65\/360) accounted for 68% (187\/276) of all STIs. Sexualized drug use (Chemsex) was reported by 44% (157\/360) of participants and was significantly associated with higher rates of gonorrhea (38% vs.\u00a021%, <jats:italic>p<\/jats:italic>\u202f&lt;\u20090.001) and syphilis (17% vs.\u00a05%, <jats:italic>p<\/jats:italic>\u202f&lt;\u20090.001) but not chlamydia (26% vs.\u00a019%, <jats:italic>p<\/jats:italic>\u202f=\u20090.118).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Throughout the study, 43% of participants experienced a\u00a0bacterial STI, which was mostly asymptomatic and at extragenital sites. Chemsex was commonly reported and identified as a\u00a0predictor for STI reinfection, underlining the importance of harm reduction strategies in Austrian STI prevention.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00508-025-02499-6","type":"journal-article","created":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T15:48:39Z","timestamp":1740930519000},"page":"571-578","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recurrence of sexually transmitted infections is commonly found in a\u00a0subpopulation of Austrian users of HIV pre-exposure prophylaxis"],"prefix":"10.1007","volume":"137","author":[{"given":"Nikolaus","family":"Urban","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Neidhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Grabmeier-Pfistershammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Touzeau-Roemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaspar Laurenz","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Strassl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Weninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Willinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang Michael","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1807-8258","authenticated-orcid":false,"given":"David","family":"Chromy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,2]]},"reference":[{"issue":"27","key":"2499_CR1","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant\u00a0RM, Lama\u00a0JR, Anderson\u00a0PL, McMahan\u00a0V, Liu\u00a0AY, Vargas\u00a0L, et\u00a0al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N\u00a0Engl J Med. 2010;363(27):2587\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1011205.","journal-title":"N Engl J Med"},{"issue":"23","key":"2499_CR2","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","volume":"373","author":"JM Molina","year":"2015","unstructured":"Molina\u00a0JM, Capitant\u00a0C, Spire\u00a0B, Pialoux\u00a0G, Cotte\u00a0L, Charreau\u00a0I, et\u00a0al. On-demand preexposure prophylaxis in men at high risk for HIV\u20111 infection. N\u00a0Engl J Med. 2015;373(23):2237\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1506273.","journal-title":"N Engl J Med"},{"issue":"5","key":"2499_CR3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/cid\/ciy182","volume":"67","author":"MW Traeger","year":"2018","unstructured":"Traeger\u00a0MW, Schroeder\u00a0SE, Wright\u00a0EJ, Hellard\u00a0ME, Cornelisse\u00a0VJ, Doyle\u00a0JS, et\u00a0al. Effects of pre-exposure prophylaxis for the prevention of human Immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a\u00a0systematic review and meta-analysis. Clin Infect Dis. 2018;67(5):676\u201386. https:\/\/doi.org\/10.1093\/cid\/ciy182.","journal-title":"Clin Infect Dis"},{"issue":"14","key":"2499_CR4","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1001\/jama.2019.2947","volume":"321","author":"MW Traeger","year":"2019","unstructured":"Traeger\u00a0MW, Cornelisse\u00a0VJ, Asselin\u00a0J, Price\u00a0B, Roth\u00a0NJ, Willcox\u00a0J, et\u00a0al. Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection. JAMA. 2019;321(14):1380\u201390. https:\/\/doi.org\/10.1001\/jama.2019.2947.","journal-title":"JAMA"},{"key":"2499_CR5","unstructured":"Deutsche AIDS Gesellschaft. Deutsch-\u00d6sterreichische leitlinien zur HIV-pr\u00e4expositionsprophylaxe. 2024. https:\/\/register.awmf.org\/assets\/guidelines\/055-008l_S2k_HIV-Praeexpositionsprophylaxe_2024-04_02.pdf."},{"issue":"2","key":"2499_CR6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/phh.0000000000001143","volume":"28","author":"ZH Kudon","year":"2022","unstructured":"Kudon\u00a0ZH, Mulatu\u00a0MS, Song\u00a0W, Heitgerd\u00a0J, Rao\u00a0S. Trends in condomless sex among MSM who participated in CDC-funded HIV risk-reduction interventions in the United States, 2012\u20132017. J\u00a0Public Health Manag Pract. 2022;28(2):170\u20133. https:\/\/doi.org\/10.1097\/phh.0000000000001143.","journal-title":"J Public Health Manag Pract"},{"issue":"5","key":"2499_CR7","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1080\/10826084.2023.2184207","volume":"58","author":"K Ivey","year":"2023","unstructured":"Ivey\u00a0K, Bernstein\u00a0KT, Kirkcaldy\u00a0RD, Kissinger\u00a0P, Edwards\u00a0OW, Sanchez\u00a0T, et\u00a0al. Chemsex drug use among a\u00a0national sample of sexually active men who have sex with men,\u2014American men\u2019s Internet survey, 2017\u20132020. Subst Use Misuse. 2023;58(5):728\u201334. https:\/\/doi.org\/10.1080\/10826084.2023.2184207.","journal-title":"Subst Use Misuse"},{"key":"2499_CR8","doi-asserted-by":"publisher","first-page":"542301","DOI":"10.3389\/fpsyt.2020.542301","volume":"11","author":"A Bohn","year":"2020","unstructured":"Bohn\u00a0A, Sander\u00a0D, K\u00f6hler\u00a0T, Hees\u00a0N, Oswald\u00a0F, Scherbaum\u00a0N, et\u00a0al. Chemsex and mental health of men who have sex with men in Germany. Front Psychiatry. 2020;11:542301. https:\/\/doi.org\/10.3389\/fpsyt.2020.542301.","journal-title":"Front Psychiatry"},{"issue":"10","key":"2499_CR9","doi-asserted-by":"publisher","first-page":"e0275618","DOI":"10.1371\/journal.pone.0275618","volume":"17","author":"E Amundsen","year":"2022","unstructured":"Amundsen\u00a0E, Haugstvedt \u00c5, Skogen\u00a0V, Berg\u00a0RC. Health characteristics associated with chemsex among men who have sex with men: results from a\u00a0cross-sectional clinic survey in Norway. PLoS ONE. 2022;17(10):e275618. https:\/\/doi.org\/10.1371\/journal.pone.0275618.","journal-title":"PLoS ONE"},{"issue":"1","key":"2499_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/1757913918778872","volume":"139","author":"A Tomkins","year":"2019","unstructured":"Tomkins\u00a0A, George\u00a0R, Kliner\u00a0M. Sexualised drug taking among men who have sex with men: a\u00a0systematic review. Perspect Public Health. 2019;139(1):23\u201333. https:\/\/doi.org\/10.1177\/1757913918778872.","journal-title":"Perspect Public Health"},{"issue":"3","key":"2499_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1089\/apc.2022.0154","volume":"37","author":"D Chromy","year":"2023","unstructured":"Chromy\u00a0D, Urban\u00a0N, Grabmeier-Pfistershammer\u00a0K, Touzeau-Roemer\u00a0V, Skoll\u00a0M, Geusau\u00a0A, et\u00a0al. High prevalence of asymptomatic sexually transmitted infections in austrian pre-exposure prophylaxis users: a\u00a0prospective observational study. AIDS Patient Care STDS. 2023;37(3):115\u20138. https:\/\/doi.org\/10.1089\/apc.2022.0154.","journal-title":"AIDS Patient Care STDS"},{"key":"2499_CR12","unstructured":"APA-OTS. Bundesregierung schafft kostenlosen zugang zu HIV-PrEP. 2024. https:\/\/www.ots.at\/presseaussendung\/OTS_20231215_OTS0044\/bundesregierung-schafft-kostenlosen-zugang-zu-hiv-prep#:~:text=Nun%20wird%20der%20Zugang%20zu,bis%20Ende%202027%20zur%20Verf%C3%BCgung."},{"issue":"12","key":"2499_CR13","doi-asserted-by":"publisher","first-page":"e0208107","DOI":"10.1371\/journal.pone.0208107","volume":"13","author":"RN Werner","year":"2018","unstructured":"Werner\u00a0RN, Gaskins\u00a0M, Nast\u00a0A, Dressler\u00a0C. Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection\u2014A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis. PLoS ONE. 2018;13(12):e208107. https:\/\/doi.org\/10.1371\/journal.pone.0208107.","journal-title":"PLoS ONE"},{"issue":"7","key":"2499_CR14","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/s2352-3018(19)30136-5","volume":"6","author":"E Hoornenborg","year":"2019","unstructured":"Hoornenborg\u00a0E, Coyer\u00a0L, Achterbergh\u00a0RCA, Matser\u00a0A, Schim van der Loeff\u00a0MF, Boyd\u00a0A, et\u00a0al. Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2\u00a0year results from a\u00a0demonstration study. Lancet HIV. 2019;6(7):e447\u2013e55. https:\/\/doi.org\/10.1016\/s2352-3018(19)30136-5.","journal-title":"Lancet HIV"},{"issue":"11","key":"2499_CR15","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1097\/qad.0000000000001874","volume":"32","author":"E Hoornenborg","year":"2018","unstructured":"Hoornenborg\u00a0E, Coyer\u00a0L, van Laarhoven\u00a0A, Achterbergh\u00a0R, de Vries\u00a0H, Prins\u00a0M, et\u00a0al. Change in sexual risk behaviour after 6\u00a0months of pre-exposure prophylaxis use: results from the amsterdam pre-exposure prophylaxis demonstration project. AIDS. 2018;32(11):1527\u201332. https:\/\/doi.org\/10.1097\/qad.0000000000001874.","journal-title":"AIDS"},{"issue":"8","key":"2499_CR16","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1136\/sextrans-2021-055215","volume":"98","author":"FJL Anato","year":"2022","unstructured":"Anato\u00a0FJL, Panagiotoglou\u00a0D, Greenwald\u00a0ZR, Blanchette\u00a0M, Trottier\u00a0C, Vaziri\u00a0M, et\u00a0al. Chemsex and incidence of sexually transmitted infections among canadian pre-exposure prophylaxis (PrEP) users in the l\u2019Actuel PrEP cohort (2013\u20132020). Sex Transm Infect. 2022;98(8):549\u201356. https:\/\/doi.org\/10.1136\/sextrans-2021-055215.","journal-title":"Sex Transm Infect"},{"issue":"12","key":"2499_CR17","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1007\/s10461-022-03730-5","volume":"26","author":"L De La Mora","year":"2022","unstructured":"De La Mora\u00a0L, Ugarte\u00a0A, Mart\u00ednez-Rebollar\u00a0M, De Lazzari\u00a0E, Garc\u00eda-Hern\u00e1ndez\u00a0D, Font\u00a0G, et\u00a0al. Chemsex practices in PrEP: beyond addiction and risk toward a\u00a0healthy sex life-baseline experiences from a\u00a0hospital-based PrEP program in barcelona, Spain. AIDS Behav. 2022;26(12):4055\u201362. https:\/\/doi.org\/10.1007\/s10461-022-03730-5.","journal-title":"AIDS Behav"},{"key":"2499_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.drugpo.2018.02.002","volume":"55","author":"C Edmundson","year":"2018","unstructured":"Edmundson\u00a0C, Heinsbroek\u00a0E, Glass\u00a0R, Hope\u00a0V, Mohammed\u00a0H, White\u00a0M, et\u00a0al. Sexualised drug use in the united kingdom (UK): a\u00a0review of the literature. Int J Drug Policy. 2018;55:131\u201348. https:\/\/doi.org\/10.1016\/j.drugpo.2018.02.002.","journal-title":"Int J Drug Policy"},{"key":"2499_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(24)00236-6","author":"JM Molina","year":"2024","unstructured":"Molina\u00a0JM, Bercot\u00a0B, Assoumou\u00a0L, Rubenstein\u00a0E, Algarte-Genin\u00a0M, Pialoux\u00a0G, et\u00a0al. Doxycycline prophylaxis and meningococcal group\u00a0B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a\u00a0multicentre, open-label, randomised trial with a\u00a02\u00a0\u00d7 2 factorial design. Lancet Infect Dis. 2024; https:\/\/doi.org\/10.1016\/s1473-3099(24)00236-6.","journal-title":"Lancet Infect Dis"},{"key":"2499_CR20","unstructured":"Centers for Disease Control and Prevention. Sexually transmitted infections treatment guidelines, 2021. 2021. https:\/\/www.cdc.gov\/std\/treatment-guidelines\/default.htm."},{"key":"2499_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/1471-2334-11-203","volume":"11","author":"RP Peters","year":"2011","unstructured":"Peters\u00a0RP, Verweij\u00a0SP, Nijsten\u00a0N, Ouburg\u00a0S, Mutsaers\u00a0J, Jansen\u00a0CL, et\u00a0al. Evaluation of sexual history-based screening of anatomic sites for chlamydia trachomatis and neisseria gonorrhoeae infection in men having sex with men in routine practice. BMC Infect Dis. 2011;11:203. https:\/\/doi.org\/10.1186\/1471-2334-11-203.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"2499_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1086\/430704","volume":"41","author":"CK Kent","year":"2005","unstructured":"Kent\u00a0CK, Chaw\u00a0JK, Wong\u00a0W, Liska\u00a0S, Gibson\u00a0S, Hubbard\u00a0G, et\u00a0al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: san Francisco, california, 2003. Clin Infect Dis. 2005;41(1):67\u201374. https:\/\/doi.org\/10.1086\/430704.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2499_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41572-019-0128-6","volume":"5","author":"M Unemo","year":"2019","unstructured":"Unemo\u00a0M, Seifert\u00a0HS, Hook\u00a0EW 3rd, Hawkes\u00a0S, Ndowa\u00a0F, Dillon\u00a0JR. Gonorrhoea. Nat Rev Dis Primers. 2019;5(1):79. https:\/\/doi.org\/10.1038\/s41572-019-0128-6.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"2499_CR24","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1016\/s1473-3099(23)00356-0","volume":"23","author":"E Williams","year":"2023","unstructured":"Williams\u00a0E, Williamson\u00a0DA, Hocking\u00a0JS. Frequent screening for asymptomatic chlamydia and gonorrhoea infections in men who have sex with men: time to re-evaluate? Lancet Infect Dis. 2023;23(12):e558\u2013e66. https:\/\/doi.org\/10.1016\/s1473-3099(23)00356-0.","journal-title":"Lancet Infect Dis"},{"key":"2499_CR25","doi-asserted-by":"publisher","first-page":"100743","DOI":"10.1016\/j.lanepe.2023.100743","volume":"34","author":"C Kenyon","year":"2023","unstructured":"Kenyon\u00a0C, Herrmann\u00a0B, Hughes\u00a0G, de Vries\u00a0HJC. Management of asymptomatic sexually transmitted infections in europe: towards a\u00a0differentiated, evidence-based approach. Lancet Reg Health Eur. 2023;34:100743. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100743.","journal-title":"Lancet Reg Health Eur"},{"issue":"5","key":"2499_CR26","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/cid\/cix439","volume":"65","author":"SM Jenness","year":"2017","unstructured":"Jenness\u00a0SM, Weiss\u00a0KM, Goodreau\u00a0SM, Gift\u00a0T, Chesson\u00a0H, Hoover\u00a0KW, et\u00a0al. Incidence of gonorrhea and chlamydia following human Immunodeficiency virus preexposure prophylaxis among men who have sex with men: a\u00a0modeling study. Clin Infect Dis. 2017;65(5):712\u20138. https:\/\/doi.org\/10.1093\/cid\/cix439.","journal-title":"Clin Infect Dis"},{"key":"2499_CR27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/1471-2458-13-606","volume":"13","author":"AR Tuite","year":"2013","unstructured":"Tuite\u00a0AR, Fisman\u00a0DN, Mishra\u00a0S. Screen more or screen more often? using mathematical models to inform syphilis control strategies. BMC Public Health. 2013;13:606. https:\/\/doi.org\/10.1186\/1471-2458-13-606.","journal-title":"BMC Public Health"},{"issue":"5","key":"2499_CR28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/OLQ.0b013e3181ca3c0a","volume":"37","author":"RT Gray","year":"2010","unstructured":"Gray\u00a0RT, Hoare\u00a0A, Prestage\u00a0GP, Donovan\u00a0B, Kaldor\u00a0JM, Wilson\u00a0DP. Frequent testing of highly sexually active gay men is required to control syphilis. Sex Transm Dis. 2010;37(5):298\u2013305. https:\/\/doi.org\/10.1097\/OLQ.0b013e3181ca3c0a.","journal-title":"Sex Transm Dis"},{"issue":"9","key":"2499_CR29","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/olq.0000000000000824","volume":"45","author":"A Tsoumanis","year":"2018","unstructured":"Tsoumanis\u00a0A, Hens\u00a0N, Kenyon\u00a0CR. Is screening for chlamydia and gonorrhea in men who have sex with men associated with reduction of the prevalence of these infections? a systematic review of observational studies. Sex Transm Dis. 2018;45(9):615\u201322. https:\/\/doi.org\/10.1097\/olq.0000000000000824.","journal-title":"Sex Transm Dis"},{"issue":"4","key":"2499_CR30","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.1016\/S2352-3018(23)00299-0","volume":"11","author":"T Vanbaelen","year":"2024","unstructured":"Vanbaelen T, Tsoumanis A, Florence E, Van Dijck C, Huis In \u2019t Veld D, Sauvage AS, et al. Effect of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gonoscreen study): results from a randomised, multicentre, controlled trial. Lancet HIV. 2024;11(4):e233\u2013e44.","journal-title":"Lancet HIV"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02499-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-025-02499-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02499-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T07:44:27Z","timestamp":1758181467000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-025-02499-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,2]]},"references-count":30,"journal-issue":{"issue":"17-18","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2499"],"URL":"https:\/\/doi.org\/10.1007\/s00508-025-02499-6","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"type":"print","value":"0043-5325"},{"type":"electronic","value":"1613-7671"}],"subject":[],"published":{"date-parts":[[2025,3,2]]},"assertion":[{"value":"12 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.\u00a0Urban received travel support from ViiV Healthcare. K.\u00a0Grabmeier-Pfistershammer served as a\u00a0speaker and\/or consultant and\/or advisory board member for ViiV, Gilead, and received travel support from ViiV Healthcare, and Gilead. B.\u00a0Willinger served as a\u00a0speaker for Gilead and advisory board member for MSD. W.\u00a0Weninger served as a\u00a0speaker, consultant and\/or advisory board member for LEO Pharma, Pfizer, Sanofi Genzyme, Eli Lilly, Novartis, Boehringer Ingelheim, AbbVie, and Janssen. W.M.\u00a0Bauer served as a\u00a0speaker and\/or consultant and\/or advisory board member for AbbVie, ViiV Healthcare and Takeda, and received travel support from AbbVie, MSD, ViiV Healthcare, and Gilead. D.\u00a0Chromy served as a\u00a0speaker and\/or consultant and\/or advisory board member for AbbVie, Gilead, and MSD, and received travel support from AbbVie, MSD, ViiV Healthcare, and Gilead. T.\u00a0Neidhart, V.\u00a0Touzeau-Roemer, K.L.\u00a0Schmidt and R.\u00a0Strassl declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}